

Adherium Announces CEO Transition

- CEO Dawn Bitz to step down for personal reasons after leading Adherium through a period of significant commercial progress
- Chief Commercial Officer John Perry appointed Interim CEO, providing leadership continuity and deep healthcare commercial expertise
- Adherium continues to execute its growth strategy across connected respiratory care, Remote Patient Monitoring and Value Based Care initiatives

Melbourne, Australia – 29 July 2026: Adherium Limited (ASX:ADR), a global leader in digital respiratory management and developer of the FDA-cleared Hailie® Smartinhaler® platform, today announces that Chief Executive Officer, Dawn Bitz, has decided to step down from her role for personal reasons. Adherium's Chief Commercial Officer, John Perry, has been appointed Interim Chief Executive Officer with immediate effect, providing leadership continuity as the Company advances its Remote Patient Monitoring and Value Based Care growth initiatives.

Adherium's Non-Executive Chair, George Baran thanked Ms Bitz for her significant contribution to the Company over the past 12 months, *"On behalf of the Board, I would like to sincerely thank Dawn for her leadership and commitment during an important period for Adherium. Dawn played a key role in establishing the Company's Remote Patient Monitoring channel, growing recurring Hailie® revenues, and positioning Adherium well to access the Value Based Care opportunities ahead of us. We thank Dawn for her contribution and wish her all the best."*

Outgoing CEO, Dawn Bitz commented, *"It has been a privilege to lead Adherium over the past year and to work alongside such a dedicated team. I am proud of the progress we have made and while the commercial opportunity ahead for Adherium is significant, what is so compelling is the potential to improve the lives of millions of people living with chronic respiratory disease. My thanks go to our employees, customers, partners and investors for their support, and I leave the Company confident in its future under John's leadership."*

Mr John Perry currently serves as Adherium's Chief Commercial Officer and has been instrumental in the Company's commercial expansion strategy. He brings more than two decades of healthcare leadership experience, including extensive expertise in commercialisation, healthcare technology, value-based care models, enterprise

partnerships and revenue growth. The Board believes Mr Perry's deep understanding of Adherium's operations, customers and strategic priorities, together with his substantial experience across the US healthcare sector, make him ideally positioned to lead the Company during this transition period.

Non-Executive Chair, George Baran said, *"John is exceptionally well qualified to lead Adherium as Interim CEO. His commercial expertise, industry relationships and understanding of the opportunities ahead for the Company will provide continuity and momentum as we continue executing our strategy. The Board is grateful that John has agreed to step into this role."*

John Perry commented, *"Adherium has built strong momentum over the past year, and I am honoured to lead the Company as Interim CEO. My focus will be on executing our commercial strategy, accelerating adoption of the Hailie® platform and building on the strong foundations established by Dawn and the broader team."*

The landmark iCARE study, delivered in partnership with Intermountain Health and CareCentra, reinforced the value of our technology and marked an important step in our transition toward value-based care. We are grateful for the support of both organisations as we work to improve patient outcomes, broaden adoption of our solutions and drive sustainable growth. I look forward to working closely with our team, customers, partners and investors as we continue to build on this momentum."

Learn more at **adherium.com**

This ASX announcement was approved and authorised for release by the Board of Adherium.

- ENDS -

Investor Enquiries

Adherium Limited
investors@adherium.com

Media Enquiries:

Haley Chartres
HACK Director
haley@hck.digital



ASX Release

About Adherium (ASX: ADR):

Adherium is a provider of integrated digital health solutions and a worldwide leader in connected respiratory medical devices, with more than 180,000 sold globally.

Adherium's Hailie® platform solution provides clinicians, healthcare providers and patients access to remotely monitor medication usage parameters and adherence, supporting reimbursement for qualifying patient management. The Hailie® solution includes a suite of integration tools to enable the capture and sharing of health data via mobile and desktop apps, Software Development Kit (SDK) and Application Programming Interface (API) integration tools, and Adherium's own broad range of sensors connected to respiratory medications. Adherium's Hailie® solution is designed to provide visibility to healthcare providers of medication use history to better understand patterns in patient respiratory disease. **Learn more at**

adherium.com